In vitro and in vivo antimicrobial activity of combined therapy of silver nanoparticles and visible blue light against Pseudomonas aeruginosa

International Journal of Nanomedicine

Volumn 11, Issue , 2016, Pages 1749-1758

  El Din, Suzanne Nour ^a   El Tayeb, Tarek A ^b   Abou Aisha, Khaled ^a   El Azizi, Mohamed ^a  

^a German University in Cairo   (Egypt)

^b Cairo University   (Egypt)

Author keywords

Biofilm; Bioplastic disc; Invasive sepsis; Murine model; Non conventional therapy; Wound colonization

Indexed keywords

SILVER NANOPARTICLE; ANTIINFECTIVE AGENT; METAL NANOPARTICLE; SILVER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BIOFILM; BLUE LIGHT; BURN; CELL DAMAGE; CHRONIC WOUND; CONTROLLED STUDY; FEMALE; HORSE; IN VITRO STUDY; IN VIVO STUDY; MALE; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PSEUDOMONAS AERUGINOSA; SEPSIS; TRANSMISSION ELECTRON MICROSCOPY; WOUND; WOUND HEALING; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; LIGHT; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PSEUDOMONAS INFECTIONS; RADIATION RESPONSE; ULTRASTRUCTURE;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOFILMS; DISEASE MODELS, ANIMAL; HORSES; LIGHT; METAL NANOPARTICLES; MICE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SEPSIS; SILVER;

EID: 84964846366     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S102398     Document Type: Article

References (45)

1. Mahendra R, Alka Y, Aniket G. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv. 2009;27:176–183.
2. D’Britto V, Kapse H, Babrekar H, et al. Silver nanoparticle studded porous polyethylene scaffolds: bacteria struggle to grow on them while mammalian cells thrive. Nanoscale. 2011;3(7):2957–2963.
3. Nowack B, Krug H, Height M. 120 years of nanosilver history: 609 Implications for policy makers. Environ Sci Technol. 2011;45(4): 1177–1183.
4. Bogumiła R, Andrea H, Andreas L, Kenneth AD, Iseult L. Mechanisms of silver nanoparticle release, transformation and toxicity: A critical review of current knowledge and recommendations for future studies and applications. Materials. 2013;6:2295–2350.
5. Xiu ZM, Zhang QB, Puppala HL, Colvin VL, Alvarez PJJ. Negligible particle-specific antibacterial activity of silver nanoparticles. Nano Lett. 2012;12(8):4271–4275.
6. Dai T, Gupta A, Murray CK, Vrahas MS, Tegos GP, Hamblin MR. Blue light for infectious diseases: Propionibacterium acnes, Helicobacter pylori, and beyond? Drug Resist Updat. 2012;15(4):223–236.
7. Maclean M, McKenzie K, Anderson JG, Gettinby G, MacGregor SJ. 405 nm light technology for the inactivation of pathogens and its potential role for environmental disinfection and infection control. J Hosp Infect. 2014;88(1):1–11.
8. Filice GA, Nyman JA, Lexau C, et al. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol. 2010;31(4):365–373.
9. Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2010;54(1):109–115.
10. Métraux GS, Mirkin CA. Rapid thermal synthesis of silver nanoprisms with chemically tailorable thickness. Adv Mater. 2005;17(4):412–415.
11. Kapoor S. Preparation, characterization, and surface modification of silver particles. Langmuir. 1998;14(5):1021–1025.
12. Clinical Laboratory Standard Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standards-Second Edition, in CLSI document M27-2A. Pennsylvania, USA: CLSI; 2002.
13. Dykstra MJ, Reuss E. Biological Electron Microscopy Theory, Techniques and Troubleshooting. 2nd ed. Germany: Springer; 2003.
14. Rupal J, Kausha J, Mallikarjuna SC, Dipt P. Preparation and evaluation of topical gel of valdecoxib. Int J Pharm Sci Drug Res. 2010;2(1): 51–54.
15. Bisbe J, Gatell JM, Puig J, et al. Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. Rev Infect Dis. 1988;10:629–635.
16. Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med. 1996;156:2121–2126.
17. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with Gram-negative bacteria. Clin Microbiol Rev. 2012;25:450–470.
18. Hill D, Rose B, Pajkos A, et al. Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microbiol. 2005;43(10):5085–5090.
19. Franci G, Falanga A, Galdiero S, et al. Silver nanoparticles as potential antibacterial agents. Molecules. 2015;20:8856–8874.
20. Elechiguerra JL, Burt JL, Morones JR, et al. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnology. 2005;3:6.
21. Cromwell WA, Yang J, Starr JL, Jo YK. Nematicidal effects of silver nanoparticles on root-knot nematode in bermudagrass. J Nematol. 2014; 46(3):261–266.
22. Pereira L, Dias N, Carvalho J, Fernandes S, Santos C, Lima N. Synthesis, characterization and antifungal activity of chemically and fungal-produced silver nanoparticles against Trichophyton rubrum. J Appl Microbiol. 2014;117(6):1601–1613.
23. Choi O, Hu Z. Size dependent and reactive oxygen species related nanosilver toxicity to nitrifying bacteria. Environ Sci Technol. 2008;42: 4583–4588.
24. Zhang M, Zhang K, De Gusseme B, Verstraete W, Field R. The antibacterial and anti-biofouling performance of biogenic silver nanoparticles by Lactobacillus fermentum. Biofouling. 2014;30:347–357.
25. Lazar V. Quorum sensing in biofilms – How to destroy the bacterial citadels or their cohesion power? Anaerobe. 2011;17:280–285.
26. Periasamy S, Joo HS, Duong AC, et al. How Staphylococcus aureus biofilms develop their characteristic structure. Proc Natl Acad Sci. 2012; 109:1281–1286.
27. Morones JR, Elechiguerra JL, Camacho A, et al. The bactericidal effect of silver nanoparticles. Nanotechnology. 2005;16:2346–2353.
28. Matsumura Y, Yoshikata K, Kunisaki S, Tsuchido T. Mode of bacterial action of silver zeolite and its comparison with that of silver nitrate. Appl Environ Microbiol. 2003;69:4278–4281.
29. Sukumaran P, Eldho KP. Silver nanoparticles: mechanism of antimicrobial action, synthesis, medical applications, and toxicity effects. Int Nano Lett. 2012;2:32.
30. Maclean M, Macgregor SJ, Anderson JG, Woolsey GA. The role of oxygen in the visible-light inactivation of Staphylococcus aureus. J Photochem Photobiol B. 2008;92(3):180–184.
31. Wu L, McGrane RS, Beattie GA. Light regulation of swarming motility in Pseudomonas syringae integrates signaling pathways mediated by a bacteriophytochrome and a LOV protein. MBio. 2013;4(3): e00334–e13.
32. Barkovits K, Schubert B, Heine S, Scheer M, Frankenberg-Dinkel N. Function of the bacteriophytochrome BphP in the RpoS/Las quorum sensing network of Pseudomonas aeruginosa. Microbiology. 2011; 157(Pt 6):1651–1664.
33. Donlan RM, Costerton JW. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15:167–193.
34. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 2004;42:1915–1922.
35. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318–1322.
36. Scher K, Romling U, Yaron S. Effect of heat, acidification, and chlorination on Salmonella enterica serovar typhimurium cells in a biofilm formed at the air-liquid Interface. Appl Environ Microbiol. 2005;71(3): 1163–1168.
37. Roe D, Karandikar B, Bonn-Savage N, Gibbins B, Roullet JB. Antimicrobial surface functionalization of plastic catheters by silver nanoparticles. J Antimicrob Chemother. 2008;61:869–876.
38. Stevens KN, Croes S, Boersma RS, et al. Hydrophilic surface coatings with embedded biocidal silver nanoparticles and sodium heparin for central venous catheters. Biomaterials. 2011;32:1264–1269.
39. Mahmoudi M, Serpooshan V. Silver-coated engineered magnetic nanoparticles are promising for the success in the fight against antibacterial resistance threat. ACS Nano. 2012;6:2656–2664.
40. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clin Microbiol Rev. 2006;19(2):403–434.
41. World Health Organization (WHO) Model List of Essential Medicines, 19th list; 2015. Available from: http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed November 10, 2015.
42. Nunan R, Harding KG, Martin P. Clinical challenges of chronic wounds: searching for an optimal animal model to recapitulate their complexity. Dis Model Mech. 2014;7(11):1205–1213.
43. Zhao G, Usui ML, Lippman SI, et al. Biofilms and inflammation in chronic wounds. Adv Wound Care. 2013;2(7):389–399.
44. Westgate SJ, Percival SL, Knottenbelt DC, Clegg PD, Cochrane CA. Microbiology of equine wounds and evidence of bacterial biofilms. Vet Microbiol. 2011;12:150–152.
45. Fjordbakk CT, Arroyo LG, Hewson J. Retrospective study of the clinical features of limb cellulitis in 63 horses. Vet Rec. 2008;162(8):233–236.